| Literature DB >> 34843640 |
Mengli Li1, Chenchen Li1, Miaomiao Hu1, Tao Zhang1,2.
Abstract
2'-Fucosyllactose (2'-FL), one of the most abundant human milk oligosaccharides (HMOs), is used as a promising infant formula ingredient owing to its multiple health benefits for newborns. However, limited availability and high-cost preparation have restricted its extensive use and intensive research on its potential functions. In this work, a powerful Escherichia coli cell factory was developed to ulteriorly increase 2'-FL production. Initially, a modular pathway engineering was strengthened to balance the synthesis pathway through different plasmid combinations with a resulting maximum 2'-FL titre of 1.45 g l-1 . To further facilitate the metabolic flux from GDP-l-fucose towards 2'-FL, the CRISPR-Cas9 system was utilized to inactivate the genes including lacZ and wcaJ, increasing the titre by 6.59-fold. Notably, the co-introduction of NADPH and GTP regeneration pathways was confirmed to be more conducive to 2'-FL formation, achieving a 2'-FL titre of 2.24 g l-1 . Moreover, comparisons of various exogenous α1,2-fucosyltransferase candidates revealed that futC from Helicobacter pylori generated the highest titre of 2'-FL. Finally, the viability of scaled-up production of 2'-FL was evidenced in a 3 l bioreactor with a maximum titre of 22.3 g l-1 2'-FL and a yield of 0.53 mole 2'-FL mole-1 lactose.Entities:
Mesh:
Substances:
Year: 2021 PMID: 34843640 PMCID: PMC9049618 DOI: 10.1111/1751-7915.13977
Source DB: PubMed Journal: Microb Biotechnol ISSN: 1751-7915 Impact factor: 6.575
Fig. 12′‐FL biosynthesis model (de novo or salvage pathway) in engineered E. coli. The genes in purple denote overexpressed enzymes, and the genes in red denote the inactivated enzymes. The abbreviations of the enzymes are as follows: manA, mannose‐6‐phosphate isomerase; manB, phosphomannomutase; manC, α‐D‐mannose‐1‐phosphate guanyltransferase; gmd, GDP‐D‐mannose‐4,6‐ehydratase; wcaG, GDP‐l‐fucose synthetase; wcaJ, UDP‐glucose lipid carrier transferase; lacZ, β‐galactosidase; zwf, glucose‐6‐phosphate dehydrogenase; Gsk, guanosine‐inosine kinase; GuaB, IMP dehydrogenase; GuaA, GMP synthetase; GuaC, GMP reductase; Gmk, guanylate kinase; Ndk, nucleotide diphosphate kinase; PntAB, membrane‐bound transhydrogenase and UdhA, soluble transhydrogenase.
Fig. 2Plasmid combinatorial optimization for 2′‐FL production. A. Schematic design of different plasmid combinations. Module I includes manB, manC, gmd and wcaG. Module II contains futC and lacY. Both modules were expressed under the control of extremely strong (pRSFDuet‐1, denoted by R), relatively strong (pETDuet‐1, denoted by E), moderate (pCDFDuet‐1, denoted by D), weak (pACYCDuet‐1, denoted by A) or very weak (pCOLADuet‐1, denoted by O) plasmids. B. Influences of modular engineering of 2′‐FL. Triplicate experiments were conducted, and error bars denote the standard deviation.
Fig. 5Relative expression levels of genes within 2′‐FL biosynthetic pathway in the engineered strains. A. Expression profiles of the genes (manB, manC, gmd, wcaG, futC and lacY) in engineered E. coli strains (BZW‐1, BZW‐5, BZW‐10, BZW‐15, BZW‐4, BZW‐8, BZW‐12 and BZW‐16). B. Effect of gene knockdown on the expression of related genes (manC, manB, gmd, wcaG, lacY, lacZ and wcaJ) in the 2′‐FL biosynthetic pathway. Statistical significance was assessed by Tukey’s HSD test. * and ** mean P < 0.05 and P < 0.01 respectively.
Fig. 3Effect of increased cofactor NADPH and GTP availability on 2′‐FL production. A. Cofactor regeneration pathways associated with the de novo pathway. The genes involved in the cofactor engineering include zwf, pntAB, UdhA, Gsk, GuaA, GuaB, GuaC, Gmk and Ndk. B. Shake flask fermentation results of different engineered strains with single and multiple gene overexpression involving cofactor regeneration. Triplicate experiments were conducted, and error bars denote the standard deviation. * and ** mean P < 0.05 and P < 0.01 respectively.
Fig. 4Effect of gene knockout on 2′‐FL biosynthesis. A. Overview of CRISPR/Cas9 genome editing strategies in E. coli. Genome editing involves three main components: (1) a pCas9 plasmid expressing the λ Red machinery and Cas9 endonuclease; (2) a pTargetF plasmid carrying the sgRNA gene; (3) a homologous repair template, donor‐DNA. B. GDP‐l‐fucose titre and DCW of BWS, BZS, BWZS and the control host BS. C. 2′‐FL titre, DCW and 2′‐FL yield on lactose in BD, BWD, BZD and BWZ‐1. Triplicate experiments were performed, and the error bars indicate the standard deviation. * and ** mean P < 0.05 and P < 0.01 respectively.
Fig. 6Fig. Biosynthesis of 2′‐FL by batch and fed‐batch fermentation. Production of 2′‐FL from glycerol with batch fermentations using several α1,2‐fucosyltransferase including HpFutC1 (A), HpFutC2 (B), Bfwcfb (C) and EcwbgL (D). (E) Production of 2′‐FL by strain BWZ24 with HpFutC1 in a 3 l bioreactor. Thick arrow, IPTG induction and initial addition of lactose; thin arrows, intermittent addition of lactose.
List of strains used in this study.
| Strains | Relevant genotype or relevant properties | Reference |
|---|---|---|
|
| F | Novagen |
|
|
| Novagen |
| BW |
| This study |
| BZ |
| This study |
| BZW |
| This study |
| BS | BL21 (DE3) harboring plasmids pRSF‐CBGW | This study |
| BD | BL21 (DE3) harboring plasmids pRSF‐CBGW and pET‐CY | This study |
| BWS | BW harboring plasmids pRSF‐CBGW | This study |
| BWD | BW harboring plasmids pRSF‐CBGW and pET‐CY | This study |
| BZS | BZ harboring plasmids pRSF‐CBGW | This study |
| BZD | BZ harboring plasmids pRSF‐CBGW and pET‐CY | This study |
| BZWS | BZW harboring plasmids pRSF‐CBGW | This study |
| BZW‐1 | BZW harboring plasmids pRSF‐CBGW and pET‐CY | This study |
| BZW‐2 | BZW harboring plasmids pRSF‐CBGW and pCDF‐CY | This study |
| BZW‐3 | BZW harboring plasmids pRSF‐CBGW and pACYC‐CY | This study |
| BZW‐4 | BZW harboring plasmids pET‐CBGW and pRSF‐CY | This study |
| BZW‐5 | BZW harboring plasmids pET‐CBGW and pCDF‐CY | This study |
| BZW‐6 | BZW harboring plasmids pET‐CBGW and pAYC‐CY | This study |
| BZW‐7 | BZW harboring plasmids pET‐CBGW and pCOLA‐CY | This study |
| BZW‐8 | BZW harboring plasmids pCDF‐CBGW and pRSF‐CY | This study |
| BZW‐9 | BZW harboring plasmids pCDF‐CBGW and pET‐CY | This study |
| BZW‐10 | BZW harboring plasmids pCDF‐CBGW and pACYC‐CY | This study |
| BZW‐11 | BZW harboring plasmids pCDF‐CBGW and pCOLA‐CY | This study |
| BZW‐12 | BZW harboring plasmids pAYC‐CBGW and pRSF‐CY | This study |
| BZW‐13 | BZW harboring plasmids pAYC‐CBGW and pET‐CY | This study |
| BZW‐14 | BZW harboring plasmids pAYC‐CBGW and pCDF‐CY | This study |
| BZW‐15 | BZW harboring plasmids pAYC‐CBGW and pCOLA‐CY | This study |
| BZW‐16 | BZW harboring plasmids pCOLA‐CBGW and pET‐CY | This study |
| BZW‐17 | BZW harboring plasmids pCOLA‐CBGW and pCDF‐CY | This study |
| BZW‐18 | BZW harboring plasmids pCOLA‐CBGW and pACYC‐CY | This study |
| BZW‐19 | BZW‐1 harboring plasmids pCDF‐ | This study |
| BZW‐20 | BZW‐1 harboring plasmids pCDF‐ | This study |
| BZW‐21 | BZW‐1 harboring plasmids pCDF‐ | This study |
| BZW‐22 | BZW‐1 harboring plasmids pCDF‐ | This study |
| BZW‐23 | BZW‐1 harboring plasmids pCDF‐ | This study |
| BZW‐24 | BZW‐1 harboring plasmids pCDF‐ | This study |
| BZW‐25 | BZW‐1 harboring plasmids pCDF‐ | This study |
| BZW‐26 | BZW‐1 harboring plasmids pCDF‐ | This study |
| BZW‐27 | BZW harboring plasmids pRSF‐CBGW, pET‐TY and pCDF‐ | This study |
| BZW‐28 | BZW harboring plasmids pRSF‐CBGW, pET‐FY and pCDF‐ | This study |
| BZW‐29 | BZW harboring plasmids pRSF‐CBGW, pET‐GY and pCDF‐ | This study |